FreeGulliver LLC’s Starling Oncology, Inc. Warrant STLNW Stock Holding History

FreeGulliver LLC’s Portfolio STLNW Stock Details STLNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-76,993	Closed	-$9.24K	–	119
2025 Q3	$9.24K	Buy	+76,993	New	+$8.79K	﹤0.01%	101
2025 Q2	–	Sell	-18,500	Closed	-$501	–	100
2025 Q1	$501	Hold	18,500	–	–	﹤0.01%	96
2024 Q4	$96	Sell	18,500 -174,601	-90%	-$2.72K	﹤0.01%	93
2024 Q3	$3.86K	Hold	193,101	–	–	﹤0.01%	84
2024 Q2	$5.08K	Buy	193,101 +76,951	+66%	+$5.93K	﹤0.01%	85
2024 Q1	$23.2K	Buy	116,150 +97,650	+528%	+$22.3K	0.02%	68
2023 Q4	$2.31K	Buy	+18,500	New	+$2.92K	﹤0.01%	44

Other funds holding STLNW

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

TCM

Tenor Capital Management New York $6.49B AUM 3% 1-Year Est. Return

FreeGulliver LLC's STLNW Position: Q4 2025 in Review

FreeGulliver LLC sold out of Starling Oncology, Inc. Warrant (STLNW) in Q4 2025, closing a stake of 76,993 shares — an estimated $9.24K sold.

FreeGulliver LLC first reported a position in STLNW in Q4 2023 and held it in 7 quarters. The position peaked at $23.2K in Q1 2024. 11 funds tracked by Wall St. Rank hold STLNW as of Q4 2025.

FreeGulliver LLC reported no remaining Starling Oncology, Inc. Warrant position as of Q4 2025 after selling out during the quarter.
FreeGulliver LLC sold 76,993 Starling Oncology, Inc. Warrant shares in Q4 2025, an estimated $9.24K.
FreeGulliver LLC first reported a position in Starling Oncology, Inc. Warrant in Q4 2023 and held it in 7 quarters.
FreeGulliver LLC's Starling Oncology, Inc. Warrant position peaked at $23.2K in Q1 2024.
11 funds tracked by Wall St. Rank held Starling Oncology, Inc. Warrant as of Q4 2025.

Based on FreeGulliver LLC's 13F filing for Q4 2025, filed 12 Feb 2026.